The largest database of trusted experimental protocols

4 protocols using gw6471

1

Ferroptosis Induction Compounds Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
The commercially available compounds used were erastin (Selleckchem S7242), nutlin-3a (Sigma-Aldrich 444152), MDMX inhibitor NSC207895 (Calbiochem 444158), staurosporine (Selleckchem S1421), deferoxamine (Calbiochem 252750), MEL23 (InterBioscreen) (Herman et al. 2011 (link)), PPARα agonist (Pirinixic acid; Selleckchem S8029), PPARα antagonist (GW6471; Santa Cruz Biotechnology CAS 436159-64-7), PPARγ antagonist (GW9662; Santa Cruz Biotechnology CAS 22978-25-2), and DGAT1 inhibitor (Cayman Chemicals A-922500).
The following compounds were synthesized: IKE as in Larraufie et al. (2015) (link), fer-1 and RSL3 as in Dixon et al. (2012) (link), and FIN56 as in Shimada et al. (2016) (link).
All compounds were dissolved in DMSO (Sigma-Aldrich D8418). The fixed concentrations of compounds used was as follows (unless otherwise mentioned): 10 µM nutlin, 14 µM MEL23, 20 µM ferrostatin-1 (Fer-1), 90 µM deferoxamine (DFO), and 5 µM MDMX inhibitor.
+ Open protocol
+ Expand
2

Blueberry Juice Antagonizes PPAR-α in NASH

Check if the same lab product or an alternative is used in the 5 most similar protocols
According to previous reports [53 (link),54 (link),55 (link)], human liver cell line HL7702 and HepG2 were selected for NASH research and purchased from Shanghai Cell bank (Chinese Academy of Science, Shanghai, China), and cultured in DMEM with 25 mM glucose, 5 mM glutamine, 10% fetal bovine serum (FBS), 100 μg/mL penicillin and 100 μg/mL streptomycin at 37 °C under a 5% CO2 environment. The cell concentrations were adjusted to 1 × 105/mL and 200 μL was added to each cell in a 96-cell plate. GW6471, a PPAR-α antagonist, was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Either 20 μg/mL GW6471 or 10 μg/mL blueberry juice, or both, was added to each cell in a 96-cell plate and further cultured for 3 days. Adherent cells were detached by using 0.1% trypsin and 0.04% EDTA and resuspended in CASYton solution (Roche Applied Science, cat. no. 05651808 001). The debris was removed using a 100-μm nylon filter (Falcon Business USA Inc., Fairfield, CT, USA). Cell concentrations were measured using a glass hemocytometer and coverslip daily.
+ Open protocol
+ Expand
3

Human Cardiac Myocyte Experiments

Check if the same lab product or an alternative is used in the 5 most similar protocols
HCMs were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA) and grown in cardiac myocyte medium supplemented with 5% fetal bovine serum (FBS), 1% cardiac myocyte growth supplement, and 1% penicillin/streptomycin solution. Cells were cultured on a poly-L-lysine-coated dish in a humidified incubator with 5% CO2 at 37°C. Cells between passages 3–5 were used in all experiments. The Safety Committee of Biological Experiments at Kaohsiung Medical University approved the use of HCMs for in vitro experimental use. The following drugs were used: fenofibrate (a PPARα agonist, Sigma), GW6471 (GW, PPARα antagonist, Santa Cruz), BQ-123 [BQ123, endothelin A receptor (ETA) antagonist, Sigma], BQ788 [BQ788, endothelin B receptor (ETB) antagonist, Sigma], PD98059 (ERK inhibitor, Cell Signaling), and SB203580 (p38 inhibitor, Cell Signaling). None of these drugs significantly influence cell viability (>90%).
+ Open protocol
+ Expand
4

Pharmacological Modulation of Inflammation

Check if the same lab product or an alternative is used in the 5 most similar protocols
β-Caryophyllene (90% pure) was procured from Sigma-Aldrich. Diclofenac sodium (PubChem CID: 5018304), capsazepine (selective TRPV1 antagonist, PubChem CID: 2733484), GW6471 (PPARα antagonist, PubChem CID: 446738) and SR141716A (CB1 antagonist, PubChem CID: 104850) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). AM630 (selective CB2 antagonist, PubChem CID: 4302963) was procured from Tocris Bioscience, UK. The antagonists were reconstituted in dimethyl sulphoxide (DMSO). The concentration of DMSO in the final dose formulations did not exceed 0.5%.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!